Denis Drygin - Jan 12, 2022 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Chief Scientific Officer
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jan 12, 2022
Transactions value $
$0
Form type
4
Date filed
1/26/2022, 03:14 PM
Next filing
Feb 7, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +400K $0.00 400K Jan 12, 2022 Common Stock 400K $0.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.